IRICoR attend the AUTM Canadian Region Meeting, May 16-18, 2022.
AUTM’s Regional Meeting invites technology transfer professionals from around the globe to network, make deals and gain valuable insights from world-class speakers and panels.
If you would like to meet with IRICoR at AUTM 2022, please contact Jean-louis Brochu, M.Sc., Senior Intellectual Property Manager, who will represent IRICoR at this event:

By email : 

As part of Effervescence, an event organized by Montréal Invivo and bringing together major players in the life sciences community, Pierre Fitzgibbon Minister of Economy and Innovation presented the Stratégie québécoise des sciences de la vie 2022-2025

IRICoR is delighted with this announcement. Challenged by COVID-19, stakeholders in the sector have mobilized and adapted to respond to the health crisis, and […]

IRICoR is delighted with the announcement made today by Epitopea, a transatlantic cancer immunotherapeutics company, on a $13.6M seed investment from a transatlantic syndicate of top-tier life sciences investors, including AdventLifeSciences, CTI Life Sciences, Cambridge Innovation Capital (CIC) and Fonds de solidarité FTQ.
The company’s proprietary technology provides an innovative approach to identifying shared, aberrantly expressed tumour specific antigens, known as […]

IRICoR is delighted with the announcement made today by ONO Pharmaceutical Co., Ltd. (“ONO”), one of Japan’s largest clinical-stage pharmaceutical companies, on signing a collaboration agreement with Domain Therapeutics S.A. (“Domain”) and University of Montreal (“UdeM”), to discover new small molecules targeting G protein-coupled receptors (GPCRs) in the treatment of a metabolic disease.
“Very early on, we identified and supported this […]

 
Aimed at research and life sciences professionals, IRICoR is very excited to invite you to its next workshop on intellectual property.
 
To mark World Intellectual Property Day, please join us on April 26, from 12:00 pm to 1:30 pm, during lunch break for this webinar on intellectual property, entitled: Patents: practical and strategic considerations
 
Our guest speaker, Mr. Alain Dumont, […]

It is with pleasure that Mrs. Nadine Beauger, President and CEO of IRICoR, went “Under the microscope” of IVADO. “Under the microscope” is a project aimed at highlighting members of its community through short portraits.
Extract from the interview: “Our flexible project development model allows us to identify complementary expertise to include artificial intelligence know-how in drug discovery projects.”
Read the interview […]

Sessions have been announced for the 7th annual Access to Innovation Conference. The virtual conference brings together all stakeholders in the life sciences sector, academia, research, health institutions, and government to share their insights into this year’s theme: Building on Excellence: A Vibrant Future for BC Life Sciences.
We are pleased to announce that IRICoR is a partner […]

 
The new issue of Premières en affaires magazine is now available. IRICoR is proud to have collaborated on this edition.
 
Nadine Beauger, President and CEO of IRICoR and Anne Marinier, Director of Medicinal Chemistry and Director of the Drug Discovery Unit at IRIC, highlight the strength of a collaborative women and the importance of combining science and business, for the ultimate […]

On Monday, December 13, Nadine Beauger, IRICoR’s President and CEO, took part in the panel discussion: Leveraging our niches of excellence, along with Stéphane Létourneau, Executive Vice President at Mila, and Stéphane Paquet, President and CEO at Montréal International. This panel was presented as part of the Strategic Forum: The pharmaceutical industry: At the forefront of life sciences, an initiative […]

Martinsried, Germany and Montréal, Canada – Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies, IRICoR, and the University of Montréal (Université de Montréal, UdeM) expand their mutual analyses of potentially novel cancer antigens.
In January 2020, Medigene entered into a research collaboration on novel cancer antigens for highly specific immunotherapies […]